Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 1590313
PUBLISHER: BCC Research | PRODUCT CODE: 1590313
Global Market Opportunities and Competitive Landscape for CDMO
PUBLISHED:
PAGES: 130 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The global CDMO market was valued at $128.0 billion in 2023. This market is expected to grow from $136.6 billion in 2024 to $191.6 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.0% from 2024 to 2029.
The global CDMO market for drug product/finished drug manufacturing services is expected to grow from $50.6 billion in 2024 to $69.7 billion by the end of 2029, at a CAGR of 6.6% from 2024 to 2029.
The global CDMO market for analytical testing and regulatory support services is expected to grow from $19.7 billion in 2024 to $29.9 billion by the end of 2029, at a CAGR of 8.7% from 2024 to 2029.
Report Scope
This report provides an overview of the pharmaceutical business and the function of contract development and manufacturing organizations (CDMOs). The analysis includes a review of the global CDMO market by service type, drug molecule type and end use. It also examines the regulatory policies, standards and inspection trends of the global CDMO markets. In addition, the competitive environment, significant rivals, significant leaders and top 10 manufacturers in the CDMO sector are also reviewed.
The report presents a detailed description of the service types (API manufacturing services, drug product/finished drug manufacturing service, pharmaceutical development services and analytical testing and regulatory support services) and current and historical market revenues. The CDMO markets are also segmented based on type of molecule (small-molecule drugs, biologics and advanced therapies) and end user (clinical and commercial). The market revenue for each geographic segment (North America, Europe, Asia-Pacific and the Rest of the World) has also been provided in the report.
In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also included in this report. For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.
Report Includes
- 76 data tables and 32 additional tables
- An overview of the global contract development and manufacturing organization (CDMO) market
- Analysis of the global market trends, with data from 2021-2022, estimates for 2023, forecast for 2024, and projections of compound annual growth rates (CAGRs) through 2029
- Estimates of the market size and revenue forecast for the CDMO market, and a corresponding market share analysis based on type of service, drug molecule type, end user, and region
- Evaluation of the market potential and opportunities for pharmaceutical CDMOs, regulatory policies, standards and inspection trends
- Identifying the pharma companies that are considered leaders in their field, as well as the technological means these companies are using to exploit their markets
- A look at the competitive landscape of the global CDMO market, featuring companies contracting with a contract manufacturing outsourcer for both clinical and commercial stage manufacturing
- A discussion of the ESG challenges and practices in the CDMO industry
- An analysis of the market shares of key companies in the industry as well as their proprietary technologies and strategic alliances
- Profiles of the leading players, including Thermo Fisher Scientific Inc., Merck KGaA, Lonza, Catalent Inc., and WuXi AppTec
Product Code: PHM238B
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
Chapter 2 Market Overview
- Overview
- Value Chain Analysis
- Small-Molecule Drugs
- Biologics
- Advanced Therapy Medical Products
- PESTEL Analysis of the Pharmaceutical Industry
- Political Factors
- Economic Factors
- Social Factors
- Technological Factors
- Environmental Factors
- Legal Factors
Chapter 3 Market Dynamics
- Global Market Dynamics
- Market Drivers
- Increase in Pharmaceutical Outsourcing Practices
- Pressure on R&D Spending
- Rising Demand for Advanced Therapeutics
- Upsurge in the Number of Clinical Trials
- Market Restraints
- Strict Regulations and Compliance Requirements
- Shortage of Skilled Technical Personnel
- Strong Competition in Cost, Technology and Service Ranges
- Market Opportunities
- Inorganic Growth
Chapter 4 Emerging Trends
- Overview
- Increased Focus on Biologics and Cell and Gene Therapy
- Integration of Digital Technologies
- Collaborative Risk Management
Chapter 5 Regulatory Landscape
- Overview
- Good Manufacturing Practice (GMP)
- Quality Assurance and Quality Control
- Regulatory Submissions
- Environmental & Safety Regulations
- International Standards
- Data Integrity & Security
- Labeling & Packaging
- Audits and Inspections
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Breakdown by Type of Service
- API Manufacturing Services
- Drug Product/Finished Drug Manufacturing Services
- Pharmaceutical Development Services
- Analytical Testing and Regulatory Support Services
- Market Breakdown by Type of Molecule
- Small-molecule Drugs
- Biologics
- Advanced Therapies
- Market Breakdown by End User
- Clinical
- Commercial
- Geographic Breakdown
- Market Breakdown by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 7 Competitive Intelligence
- Overview
- New Entrants in Market
- Global Market Shares of Leading Companies
Chapter 8 Sustainability in CDMO Market: ESG Perspective
- Overview
- Green Chemistry and Pharmaceutical Manufacturing
- Considering Sustainability through the Development Cycle and Across the Supply Chain
- Sustainability in the CDMO industry
- Environmental Considerations
- Social Considerations
- Governance Factors
- ESG Risk Ratings
- Conclusion
Chapter 9 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- CATALENT INC.
- FUJIFILM DIOSYNTH BIOTECHNOLOGIES
- LONZA
- MERCK KGAA
- RECIPHARM AB
- SAMSUNG BIOLOGICS
- SIEGFRIED HOLDING AG
- THERMO FISHER SCIENTIFIC INC.
- WUXI APPTEC
Product Code: PHM238B
List of Tables
- Summary Table : Global CDMO Market, by Type of Service, Through 2029
- Table 1 : Global CDMO Market, by Type of Service, Through 2029
- Table 2 : Global CDMO Market for API Manufacturing Services, by Region, Through 2029
- Table 3 : Global CDMO Market for Drug Product/Finished Drug Manufacturing Services, by Region, Through 2029
- Table 4 : Global CDMO Market for Pharmaceutical Development Services, by Region, Through 2029
- Table 5 : Global CDMO Market for Analytical Testing and Regulatory Support Services, by Region, Through 2029
- Table 6 : Global CDMO Market, by Type of Molecule, Through 2029
- Table 7 : Global CDMO Market for Small-molecule Drugs, by Region, Through 2029
- Table 8 : Global CDMO Market for Biologics, by Region, Through 2029
- Table 9 : Global CDMO Market for Advanced Therapies, by Region, Through 2029
- Table 10 : Global CDMO Market, by End User, Through 2029
- Table 11 : Global CDMO Market for Clinical Services, by Region, Through 2029
- Table 12 : Global CDMO Market for Commercial Services, by Region, Through 2029
- Table 13 : Global Market for CDMO, by Region, Through 2029
- Table 14 : North American CDMO Market, by Types of Service, Through 2029
- Table 15 : North American CDMO Market, by Type of Molecule, Through 2029
- Table 16 : North American CDMO Market, by End User, Through 2029
- Table 17 : North American Market for CDMO, by Country, Through 2029
- Table 18 : The U.S. CDMO Market, by Types of Service, Through 2029
- Table 19 : The U.S. CDMO Market, by Type of Molecule, Through 2029
- Table 20 : The U.S. CDMO Market, by End User, Through 2029
- Table 21 : Canadian CDMO Market, by Types of Service, Through 2029
- Table 22 : Canadian CDMO Market, by Type of Molecule, Through 2029
- Table 23 : Canadian CDMO Market, by End User, Through 2029
- Table 24 : Mexican CDMO Market, by Types of Service, Through 2029
- Table 25 : Mexican CDMO Market, by Type of Molecule, Through 2029
- Table 26 : Mexican CDMO Market, by End User, Through 2029
- Table 27 : European CDMO Market, by Types of Service, Through 2029
- Table 28 : European CDMO Market, by Type of Molecule, Through 2029
- Table 29 : European CDMO Market, by End User, Through 2029
- Table 30 : European Market for CDMO Market, by Country, Through 2029
- Table 31 : German CDMO Market, by Types of Service, Through 2029
- Table 32 : German CDMO Market, by Type of Molecule, Through 2029
- Table 33 : German CDMO Market, by End User, Through 2029
- Table 34 : The U.K. CDMO Market, by Types of Service, Through 2029
- Table 35 : The U.K. CDMO Market, by Type of Molecule, Through 2029
- Table 36 : The U.K. CDMO Market, by End User, Through 2029
- Table 37 : French CDMO Market, by Types of Service, Through 2029
- Table 38 : French CDMO Market, by Type of Molecule, Through 2029
- Table 39 : French CDMO Market, by End User, Through 2029
- Table 40 : Spanish CDMO Market, by Types of Service, Through 2029
- Table 41 : Spanish CDMO Market, by Type of Molecule, Through 2029
- Table 42 : Spanish CDMO Market, by End User, Through 2029
- Table 43 : Italian CDMO Market, by Types of Service, Through 2029
- Table 44 : Italian CDMO Market, by Type of Molecule, Through 2029
- Table 45 : Italian CDMO Market, by End User, Through 2029
- Table 46 : Rest of European Countries' CDMO Market, by Types of Service, Through 2029
- Table 47 : Rest of European Countries' CDMO Market, by Type of Molecule, Through 2029
- Table 48 : Rest of European Countries' CDMO Market, by End User, Through 2029
- Table 49 : Asia-Pacific CDMO Market, by Types of Service, Through 2029
- Table 50 : Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
- Table 51 : Asia-Pacific CDMO Market, by End User, Through 2029
- Table 52 : Asia-Pacific Market for CDMO, by Country, Through 2029
- Table 53 : Chinese CDMO Market, by Types of Service, Through 2029
- Table 54 : Chinese CDMO Market, by Type of Molecule, Through 2029
- Table 55 : Chinese CDMO Market, by End User, Through 2029
- Table 56 : Japanese CDMO Market, by Types of Service, Through 2029
- Table 57 : Japanese CDMO Market, by Type of Molecule, Through 2029
- Table 58 : Japanese CDMO Market, by End User, Through 2029
- Table 59 : Indian CDMO Market, by Types of Service, Through 2029
- Table 60 : Indian CDMO Market, by Type of Molecule, Through 2029
- Table 61 : Indian CDMO Market, by End User, Through 2029
- Table 62 : Rest of Asia-Pacific CDMO Market, by Types of Service, Through 2029
- Table 63 : Rest of Asia-Pacific CDMO Market, by Type of Molecule, Through 2029
- Table 64 : Rest of Asia-Pacific CDMO Market, by End User, Through 2029
- Table 65 : Rest of the World CDMO Market, by Types of Service, Through 2029
- Table 66 : Rest of the World CDMO Market, by Type of Molecule, Through 2029
- Table 67 : Rest of the World CDMO Market, by End User, Through 2029
- Table 68 : ESG Risk Rankings for CDMO Companies, 2024*
- Table 69 : Information Sources in this Report
- Table 70 : Glossary of Terms Used in the Global CDMO Market
- Table 71 : Boehringer Ingelheim International GmbH: Company Snapshot
- Table 72 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023
- Table 73 : Boehringer Ingelheim International GmbH: Product Portfolio
- Table 74 : Boehringer Ingelheim International GmbH: News/Recent Developments, 2021
- Table 75 : Catalent Inc.: Company Snapshot
- Table 76 : Catalent Inc.: Financial Performance, FY 2022 and 2023
- Table 77 : Catalent Inc.: Product Portfolio
- Table 78 : Catalent Inc.: News/Key Developments, 2022-2024
- Table 79 : Fujifilm Diosynth Biotechnologies: Company Snapshot
- Table 80 : Fujifilm Diosynth Biotechnologies: Product Portfolio
- Table 81 : Fujifilm Diosynth Biotechnologies: News/Key Developments, 2021-2024
- Table 82 : Lonza: Company Snapshot
- Table 83 : Lonza: Financial Performance, FY 2022 and 2023
- Table 84 : Lonza: Product Portfolio
- Table 85 : Lonza: News/Key Developments, 2022-2024
- Table 86 : Merck KGaA: Company Snapshot
- Table 87 : Merck KGaA: Financial Performance, FY 2022 and 2023
- Table 88 : Merck KGaA: Product Portfolio
- Table 89 : Merck KGaA: News/Key Developments, 2022
- Table 90 : Recipharm AB: Company Snapshot
- Table 91 : Recipharm AB: Product Portfolio
- Table 92 : Recipharm AB: News/Key Developments, 2021-2024
- Table 93 : Samsung Biologics: Company Snapshot
- Table 94 : Samsung Biologics: Financial Performance, FY 2022 and 2023
- Table 95 : Samsung Biologics: Product Portfolio
- Table 96 : Samsung Biologics: News/Key Developments, 2021-2024
- Table 97 : Siegfried Holding AG: Company Snapshot
- Table 98 : Siegfried Holding AG: Financial Performance, FY 2022 and 2023
- Table 99 : Siegfried Holding AG: Product Portfolio
- Table 100 : Siegfried Holding AG: News/Key Developments, 2022-2024
- Table 101 : Thermo Fisher Scientific Inc.: Company Snapshot
- Table 102 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2022 and 2023
- Table 103 : Thermo Fisher Scientific Inc.: Product Portfolio
- Table 104 : WuXi AppTec: Company Snapshot
- Table 105 : WuXi AppTec: Financial Performance, FY 2022 and 2023
- Table 106 : WuXi AppTec: Product Portfolio
- Table 107 : WuXi AppTec: News/Key Developments, 2022-2024
List of Figures
- Summary Figure : Global CDMO Market, by Type of Service, 2021-2029
- Figure 1 : Pharma Services Value Chain
- Figure 2 : Market Dynamics of Global CDMO Market
- Figure 3 : Global CDMO Market Share, by Type of Service, 2023
- Figure 4 : Global CDMO Market Share for API Manufacturing Services, by Region, 2023
- Figure 5 : Global CDMO Market Share for Drug Product/Finished Drug Manufacturing Services, by Region, 2023
- Figure 6 : Global CDMO Market Share for Pharmaceutical Development Services, by Region, 2023
- Figure 7 : Global CDMO Market Share for Analytical Testing and Regulatory Support Services, by Region, 2023
- Figure 8 : Global CDMO Market Share, by Type of Molecule, 2023
- Figure 9 : Small-molecule NCE and Biologics Approved by FDA, 2018-2023
- Figure 10 : Global CDMO Market Share for Small-molecule Drugs, by Region, 2023
- Figure 11 : Global CDMO Market Share for Biologics, by Region, 2023
- Figure 12 : Global CDMO Market Share for Advanced Therapies, by Region, 2023
- Figure 13 : Global CDMO Market Share, by End User, 2023
- Figure 14 : Global CDMO Market Share for Clinical Services, by Region, 2023
- Figure 15 : Global CDMO Market Share for Commercial Services, by Region, 2023
- Figure 16 : Global CDMO Market Share, by Region, 2023
- Figure 17 : North American CDMO Market Share, by Types of Service, 2023
- Figure 18 : North American CDMO Market Share, by Type of Molecule, 2023
- Figure 19 : North American CDMO Market Share, by End User, 2023
- Figure 20 : North American CDMO Market Share, by Country, 2023
- Figure 21 : European CDMO Market Share, by Types of Service, 2023
- Figure 22 : European CDMO Market Share, by Type of Molecule, 2023
- Figure 23 : European CDMO Market Share, by End User, 2023
- Figure 24 : European CDMO Market Share, by Country, 2023
- Figure 25 : Asia-Pacific CDMO Market Share, by Types of Service, 2023
- Figure 26 : Asia-Pacific CDMO Market Share, by Type of Molecule, 2023
- Figure 27 : Asia-Pacific CDMO Market Share, by End User, 2023
- Figure 28 : Asia-Pacific CDMO Market Share, by Country, 2023
- Figure 29 : Rest of the World CDMO Market Share, by Types of Service, 2023
- Figure 30 : Rest of the World CDMO Market Share, by Type of Molecule, 2023
- Figure 31 : Rest of the World CDMO Market Share, by End User, 2023
- Figure 32 : Global Company Share Analysis of CDMO, 2023
- Figure 33 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023
- Figure 34 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023
- Figure 35 : Catalent Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 36 : Catalent Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 37 : Lonza: Revenue Share, by Business Unit, FY 2023
- Figure 38 : Lonza: Revenue Share, by Country/Region, FY 2023
- Figure 39 : Merck KGaA: Revenue Share, by Business Unit, FY 2023
- Figure 40 : Merck KGaA: Revenue Share, by Country/Region, FY 2023
- Figure 41 : Samsung Biologics: Revenue Share, by Business Unit, FY 2023
- Figure 42 : Samsung Biologics: Revenue Share, by Country/Region, FY 2023
- Figure 43 : Siegfried Holding AG: Revenue Share, by Business Unit, FY 2023
- Figure 44 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, FY 2023
- Figure 45 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, FY 2023
- Figure 46 : WuXi AppTec: Revenue Share, by Business Unit, FY 2023
- Figure 47 : WuXi AppTec: Revenue Share, by Country/Region, FY 2023
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.